Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8611 to 8625 of 8973 results

  1. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

  2. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued Reference number: GID-TAG320

  3. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]

    In development Reference number: GID-TA11556 Expected publication date: TBC

  4. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC

  5. Botulinum toxin type A for preventing episodic migraine [ID6450]

    In development Reference number: GID-TA11505 Expected publication date: TBC

  6. Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]

    In development Reference number: GID-TA11607 Expected publication date: TBC

  7. Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

    In development Reference number: GID-HST10037 Expected publication date: TBC

  8. GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain

    In development Reference number: GID-MT567 Expected publication date: TBC

  9. Palforzia for treating peanut allergy in children and young people (TA769)

    NICE has withdrawn this guidance. This is because Stallergenes Greer have discontinued the Palforzia initial dose escalation pack. No new people will start taking Palforzia in the UK. Healthcare professionals should discuss alternative treatment options. People currently having Palforzia will be able to continue until March 2027.

  10. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]

    In development Reference number: GID-TA11586 Expected publication date: TBC

  11. Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]

    Discontinued Reference number: GID-TA10199

  12. Farco-fill Protect for indwelling urinary catheterisation (MIB121)

    July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.

  13. Faster, fairer access to HealthTech under new national programme

    People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).

  14. Improving outcomes in urological cancers (CSG2)

    NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.